Full Press Release Details
PONTE VEDRA, Fla. , Jan. 24, 2024 — Cadrenal Therapeutics, Inc. , (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with certain conditions, announced today that Douglas Losordo , M.D., Chief Medical Officer of Cadrenal, will participate in a fireside chat moderated by Joe Pantginis , Ph.D., Managing Director of Research at H.C. Wainwright & Co., at the Lytham Partners 2024 Investor Select Conference. Management will also host one-on-one meetings with investors.
Company Webcast The webcasted fireside chat will take place at 11:00 am ET on Thursday, February 1, 2024 . The webcast can be accessed at https://wsw.com/webcast/lytham10/cvkd/2081408 or on the Company’s website at https://www.cadrenal.com/investors/ . The webcast will also be available for replay following the event.
1×1 Meetings Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1×1@lythampartners.com or register for the event at https://lythampartners.com/select2024invreg/ .
Further information on the conference is available at https://lythampartners.com/select2024 .
ABOUT CADRENAL THERAPEUTICS, INC. Cadrenal Therapeutics is developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner), to prevent heart attacks, strokes, and deaths due to blood clots in patients with certain conditions. Tecarfarin has orphan drug and fast track designations for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end stage kidney disease (ESKD) and atrial fibrillation (AFib). Tecarfarin is specifically designed to leverage a different metabolism pathway than the oldest and most commonly prescribed Vitamin K Antagonist (warfarin). Tecarfarin has been evaluated in eleven (11) human clinical trials and more than 1,000 individuals. In Phase 1, Phase 2, and Phase 2/3 clinical trials, tecarfarin has generally been well-tolerated in both healthy adult subjects and patients with chronic kidney disease. For more information, please visit: www.cadrenal.com .
For more information, please contact: